Lupin

Lupin Gains 1% After Launching Generic Oracea Capsules in US

April 10, 2024 by Nilim Daimari

In the early trading session on April 10, Lupin witnessed a 1% increase following the introduction of its inaugural generic rendition of Oracea (doxycycline capsules) in the US market. At 9:32 am, Lupin’s shares were quoted at Rs 1,621.30, marking a gain of Rs 16.25, or 1.01%, on the Bombay Stock Exchange (BSE). According to … Read more

Lupin, Glenmark, and Natco Issue Product Recalls in US Markets Over Safety Issues

April 11, 2024April 9, 2024 by Nilim Daimari

Three leading Indian pharmaceutical companies, Lupin Ltd, Glenmark Pharmaceuticals Ltd, and Natco Pharma Ltd, have commenced recalls of numerous products from the US markets, as disclosed in the latest Enforcement Report by the US Food and Drug Administration (FDA). Lupin’s recall pertains to 26,352 bottles of Rifampin capsules, a vital treatment for various forms of … Read more